Sanofi (SNYNF)

90.90
OTC Markets
Prev Close 90.90
Day Low/High 0.00 / 0.00
52 Wk Low/High 78.25 / 95.00
Exchange OTC Markets
Shares Outstanding 1253.01B
Market Cap 113.90B
Div & Yield N.A. (N.A)

Latest News

Sanofi Shares Hit 18-Month High As Genzyme and Consumer Goods Deliver Strong Q1

Sanofi Shares Hit 18-Month High As Genzyme and Consumer Goods Deliver Strong Q1

The French drugs maker lead gainers in the Paris market after profits beat analyst consensus by about 13%.

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

U.S. and European Markets Are Heading for a Fall: Exane BNP

U.S. and European Markets Are Heading for a Fall: Exane BNP

Investors are discounting U.S. political risk and a mature economic cycle that will weigh on company earnings, said the French broker which expects a 'material pullback' in 2017.

Actelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNP

Actelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNP

The chances of the French drug company muscling in on Johnson & Johnson's talks with Actelion are slim, based on Sanofi's cost of capital vs. return from a possible deal.

Sanofi Gains Boost from MS Treatments as Diabetes Drug Lantus Flounders

Sanofi Gains Boost from MS Treatments as Diabetes Drug Lantus Flounders

The thwarted Medivation bidder lifts its full-year earnings estimates and announces a share buyback program.

What to Watch in Sanofi's Third-Quarter Results

What to Watch in Sanofi's Third-Quarter Results

Slower declines in diabetes drug sales and an acceleration in new oncology treatment Praluent are key to a good quarter for the French drugs maker.

Pharmacia Drug Sales Dip but Earnings Jump

Pharmacia Drug Sales Dip but Earnings Jump

The sale of its stake in a private company boosts profits for the drugmaker.